JP2015522601A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015522601A5 JP2015522601A5 JP2015522100A JP2015522100A JP2015522601A5 JP 2015522601 A5 JP2015522601 A5 JP 2015522601A5 JP 2015522100 A JP2015522100 A JP 2015522100A JP 2015522100 A JP2015522100 A JP 2015522100A JP 2015522601 A5 JP2015522601 A5 JP 2015522601A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- disease
- macular degeneration
- onset
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000002780 macular degeneration Diseases 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 21
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 15
- 208000027073 Stargardt disease Diseases 0.000 claims description 13
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 13
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 12
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 claims description 10
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 10
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 claims description 10
- 229960004047 acamprosate Drugs 0.000 claims description 10
- 229960000794 baclofen Drugs 0.000 claims description 10
- 208000011325 dry age related macular degeneration Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 230000033115 angiogenesis Effects 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 2
- 239000000790 retinal pigment Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 238000013268 sustained release Methods 0.000 claims 3
- 239000012730 sustained-release form Substances 0.000 claims 3
- 239000005562 Glyphosate Substances 0.000 claims 1
- 201000007737 Retinal degeneration Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 159000000007 calcium salts Chemical class 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- XDDAORKBJWWYJS-UHFFFAOYSA-N glyphosate Chemical compound OC(=O)CNCP(O)(O)=O XDDAORKBJWWYJS-UHFFFAOYSA-N 0.000 claims 1
- 229940097068 glyphosate Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000004258 retinal degeneration Effects 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 5
- 230000000366 juvenile effect Effects 0.000 description 3
- 208000008069 Geographic Atrophy Diseases 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000038015 macular disease Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 210000001116 retinal neuron Anatomy 0.000 description 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261672893P | 2012-07-18 | 2012-07-18 | |
| US61/672,893 | 2012-07-18 | ||
| PCT/EP2013/065209 WO2014013025A1 (en) | 2012-07-18 | 2013-07-18 | Baclofen and acamprosate based therapy of macular degeneration disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015522601A JP2015522601A (ja) | 2015-08-06 |
| JP2015522601A5 true JP2015522601A5 (enExample) | 2017-11-16 |
| JP6271539B2 JP6271539B2 (ja) | 2018-01-31 |
Family
ID=48794112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015522100A Expired - Fee Related JP6271539B2 (ja) | 2012-07-18 | 2013-07-18 | バクロフェン及びアカンプロセートに基づいた黄斑変性疾患の治療法 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9545389B2 (enExample) |
| EP (1) | EP2874617B1 (enExample) |
| JP (1) | JP6271539B2 (enExample) |
| KR (1) | KR20150058159A (enExample) |
| CN (1) | CN104780917B (enExample) |
| AU (1) | AU2013291970B2 (enExample) |
| BR (1) | BR112015001090A2 (enExample) |
| CA (1) | CA2879114A1 (enExample) |
| EA (1) | EA029157B1 (enExample) |
| ES (1) | ES2729208T3 (enExample) |
| IL (1) | IL236737B (enExample) |
| IN (1) | IN2015DN00820A (enExample) |
| MX (1) | MX364232B (enExample) |
| NZ (1) | NZ704280A (enExample) |
| SG (1) | SG11201500309VA (enExample) |
| WO (1) | WO2014013025A1 (enExample) |
| ZA (1) | ZA201500663B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2727587A1 (en) * | 2012-10-30 | 2014-05-07 | Pharnext | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level |
| EP3062782A1 (en) | 2013-10-30 | 2016-09-07 | Pharnext | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level |
| WO2015121218A1 (en) | 2014-02-11 | 2015-08-20 | Pharnext | Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6927036B2 (en) | 2002-02-19 | 2005-08-09 | Xero Port, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
| KR20110097942A (ko) | 2003-08-20 | 2011-08-31 | 제노포트 인코포레이티드 | 아실옥시알킬 카르바메이트 프로드러그, 합성 및 사용 방법 |
| WO2005027950A1 (en) * | 2003-09-12 | 2005-03-31 | Ray And Terry's Health Products, Inc. | Eye nutritional supplement |
| ES2405329T3 (es) | 2003-12-30 | 2013-05-30 | Xenoport, Inc. | Síntesis de profármacos de carbarnato de aciloxialquilo y productos intermedios de los mismos |
| ATE511392T1 (de) | 2007-01-11 | 2011-06-15 | Xenoport Inc | Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit |
| WO2009004082A2 (en) * | 2007-07-05 | 2009-01-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anticonvulsive pharmaceutical compositions |
| US20090082464A1 (en) | 2007-09-07 | 2009-03-26 | Bernd Jandeleit | Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
| WO2009033069A1 (en) | 2007-09-07 | 2009-03-12 | Xenoport, Inc. | Simple pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
| US20090099253A1 (en) | 2007-10-15 | 2009-04-16 | Xenoport, Inc. | Internally Masked Neopentyl Sulfonyl Ester Cyclization Release Prodrugs of Acamprosate, Compositions Thereof, and Methods of Use |
| WO2009061934A1 (en) | 2007-11-06 | 2009-05-14 | Xenoport, Inc. | Use of prodrugs of gaba b agonists for treating neuropathic and musculoskeletal pain |
| US20100137442A2 (en) | 2008-02-01 | 2010-06-03 | Xenoport, Inc. | Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment |
| WO2009096985A1 (en) | 2008-02-01 | 2009-08-06 | Xenoport, Inc. | Sustained release particulate oral dosage forms of (r)-baclofen prodrugs and methods of treatment |
| WO2010089355A1 (en) | 2009-02-04 | 2010-08-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Taurine or taurine-like substances for the prevention and treatment of a disease associated with retinal ganglion cell degeneration |
| CA2753057C (en) * | 2009-03-03 | 2018-09-11 | Xenoport, Inc. | Sustained release oral dosage forms of an r-baclofen prodrug |
| JP2012524065A (ja) | 2009-04-17 | 2012-10-11 | ゼノポート，インコーポレーテッド | ＧＡＢＡＢ受容体リガンドとしてのγ−アミノ酪酸誘導体 |
| SI2560631T1 (sl) * | 2011-03-01 | 2014-06-30 | Pharnext | Na baklofenu in akamprosatu temeljeäśa terapija nevroloĺ kih nepravilnosti |
-
2013
- 2013-07-18 EP EP13737622.4A patent/EP2874617B1/en not_active Not-in-force
- 2013-07-18 WO PCT/EP2013/065209 patent/WO2014013025A1/en not_active Ceased
- 2013-07-18 IN IN820DEN2015 patent/IN2015DN00820A/en unknown
- 2013-07-18 MX MX2015000777A patent/MX364232B/es active IP Right Grant
- 2013-07-18 JP JP2015522100A patent/JP6271539B2/ja not_active Expired - Fee Related
- 2013-07-18 KR KR1020157004145A patent/KR20150058159A/ko not_active Ceased
- 2013-07-18 ES ES13737622T patent/ES2729208T3/es active Active
- 2013-07-18 BR BR112015001090A patent/BR112015001090A2/pt not_active IP Right Cessation
- 2013-07-18 NZ NZ704280A patent/NZ704280A/en not_active IP Right Cessation
- 2013-07-18 CN CN201380048663.4A patent/CN104780917B/zh not_active Expired - Fee Related
- 2013-07-18 SG SG11201500309VA patent/SG11201500309VA/en unknown
- 2013-07-18 AU AU2013291970A patent/AU2013291970B2/en not_active Ceased
- 2013-07-18 US US14/415,994 patent/US9545389B2/en not_active Expired - Fee Related
- 2013-07-18 CA CA2879114A patent/CA2879114A1/en not_active Abandoned
- 2013-07-18 EA EA201500143A patent/EA029157B1/ru not_active IP Right Cessation
-
2015
- 2015-01-15 IL IL236737A patent/IL236737B/en active IP Right Grant
- 2015-01-29 ZA ZA2015/00663A patent/ZA201500663B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2923685C (en) | Application of r-ketamine and salt thereof as pharmaceuticals | |
| RU2018110647A (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| BR112016015763B8 (pt) | preparação farmacêutica incluindo composto de ácido piridilaminocético, e, uso da mesma | |
| BRPI0819081A8 (pt) | Formulação oftálmica aquosa, processo para preparar a mesma, e, método para inibir, tratar ou prevenir doenças oculares e doença ou condição relacionada, em um paciente em necessidade de tal tratamento | |
| BR112016025997A8 (pt) | compostos para tratamento de doenças e lesões oftalmológicas, uma composição farmacêutica e uma formulação oftálmica | |
| EA201790406A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| WO2016210372A3 (en) | Methods to treat neurological diseases | |
| US20240366578A1 (en) | Treatment of pain and vasoconstriction | |
| HK1199726A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| CN103533930A (zh) | 用于治疗神经性疼痛的大麻素类化合物 | |
| HK1219943A1 (zh) | 用於治疗眼科疾病和障害的取代3-苯基丙胺衍生物 | |
| CA2986891C (en) | Compositions for use in treating parkinson's disease and related disorders | |
| CN110114083A (zh) | 一种预防和治疗脂肪肝的方法 | |
| JP2015512432A5 (enExample) | ||
| JP2015535247A5 (enExample) | ||
| EA202193190A1 (ru) | Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов | |
| WO2018005801A3 (en) | Novel non-systemic tgr5 agonists | |
| WO2009003694A3 (en) | Method for treating diseases related to mitochondrial dysfunction | |
| AU2019287528A1 (en) | Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer | |
| PH12020550722A1 (en) | Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye | |
| JP2019529569A5 (enExample) | ||
| JP2018529747A5 (enExample) | ||
| WO2016122288A3 (ko) | 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제 | |
| BR112023022561A2 (pt) | Métodos e composições para o tratamento de retinopatia diabética e condições relacionadas | |
| JP7744419B2 (ja) | レット症候群を治療するためのプリドピジンまたはその類似体の使用 |